Synlogic Inc SYBX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | OTC MARKETS |
| Currency | USD |
| IPO Date | 2015-09-30 |
| Shares Out. | 12,250,000 |
| Website | synlogictx.com/ ↗ |
| Phone | 16176592802 |
| Employees | 1 |
| Revenue | $0 |
| Net Income | -$2.3M |
| Free Cash Flow | -$4.0M |
| Total Assets | $16.6M |
| Total Liabilities | $6.2M |
| Equity | $10.3M |
About Synlogic Inc
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Synlogic Inc is a publicly traded company under the ticker symbol SYBX on the OTC MARKETS, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2025-05-01)